Certain Wegovy Strengths Expected to Be in Short Supply
Wegovy is a glucagon-like peptide-1 receptor agonist.
Diagnosis & Disease Information
Exercise and Liraglutide Reduces Metabolic Syndrome Severity in Obese Adults
Researchers sought to reduce cardiometabolic risk in patients with obesity by placing them on a low calorie diet and a combination of exercise and liraglutide.
Olezarsen Fast Tracked for Familial Chylomicronemia Syndrome
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Skyclarys Approved for Friedreich Ataxia
Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress.
Livmarli Approval Expands to Infants as Young as 3 Months With Alagille Syndrome
Previously, the treatment had been approved for patients 1 year of age and older.
Patisiran Under Review for Cardiomyopathy of ATTR Amyloidosis
The sNDA is supported by data from the phase 3, placebo-controlled APOLLO-B study.
Pozelimab Gets Priority Review for CHAPLE, a Rare Hereditary Immune Disease
CHAPLE disease is a rare genetic disorder caused by mutations in the CD55 gene.
Autism May Be a Risk Factor for Cardiometabolic Diseases, Especially in Youth
Investigators from Texas Tech University searched publication databases for studies evaluating risk for diabetes mellitus, hypertension, dyslipidemia, and atherosclerotic macrovascular disease in the setting of ASD.
Lamzede Approved for Noncentral Nervous System Manifestations of Alpha-Mannosidosis
Velmanase alfa is a recombinant form of human lysosomal alpha-mannosidase intended to provide or supplement natural alpha-mannosidase.
Tirzepatide Superior to Placebo in Weight Loss Study
The SURMOUNT-1 trial evaluated tirzepatide as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity or are overweight.
- Loading...
Loading...
Next post in News
Loading... 
Loading...